New set-up for IT at Bayer

BayerBayer is transforming its IT function to further accelerate the digitalization of the company. Leading IT providers will take over standardized services, such as the provision of digital workplaces for employees or the global operation of IT infrastructure. Internally, the IT function will focus on differentiating solutions for Bayer's businesses. The realignment is part of the efficiency and structural measures that Bayer announced back in November 2018.

"We're not only looking to achieve savings but to use this opportunity to establish a new set-up for our IT function. The goal is to deliver new solutions in health and agriculture much faster," says Wolfgang Nickl, Chief Financial Officer and member of the Board of Management at Bayer. "The support of external partners is essential for Bayer - and that's why we have chosen leading providers that we are already working with," adds Daniel Hartert, Chief Information Officer at Bayer. The partners will take on around 950 IT employees (full-time equivalents) from Bayer in Germany. The following strategic partners have been selected:

  • Atos for Global Workplace Services and Security Operations
  • Capgemini for Business Intelligence Analytics and Controlling (BIAC), Enterprise Resource Planning (excluding HR), global IT Infrastructure, Service Integration, and Unified Communications & Collaboration
  • Cognizant for IT solutions in the areas of Research & Development, Product Supply and Marketing & Sales for the Crop Science Division
  • Tata Consultancy Services for IT solutions in the areas of Research & Development, Product Supply and Marketing & Sales for the Consumer Health and Pharmaceuticals divisions, the corporate functions and HR IT

The six-year contract can be extended by one year. The respective employees in Germany will be moving to the partners in the coming months. "Parting ways with so many employees is not easy. However, this change also comes with opportunities. We are convinced that our IT colleagues will have good development prospects with the specialized providers. The respective activities will not be continued at Bayer," says Hartert.

Internally, the Bayer IT function will be organized in agile teams that are closely linked to the businesses. The aim is to digitalize the whole value chain: from research and development to product supply, marketing and sales.

About Bayer

Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Its products and services are designed to benefit people by supporting efforts to overcome the major challenges presented by a growing and aging global population. At the same time, the Group aims to increase its earning power and create value through innovation and growth. Bayer is committed to the principles of sustainable development, and the Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2018, the Group employed around 117,000 people and had sales of 39.6 billion euros. Capital expenditures amounted to 2.6 billion euros, R&D expenses to 5.2 billion euros.

Most Popular Now

COVID-19 can trigger self-attacking antibodies

Infection with the virus that causes COVID-19 can trigger an immune response that lasts well beyond the initial infection and recovery - even among people who had mild sy...

Stopping dementia at the nose with combination of …

Dementia is thought to occur when proteins called amyloid-β, tau, and α-synuclein accumulate in the brain and form oligomers. A research group from the Department of Tran...

Treatments in weeks, not months: Scientists develo…

An international team of scientists has created a plan for an accelerated pipeline for developing drug cocktails to battle the COVID-19 pandemic. The pipeline could speed...

COVID-19 - Omicron: resistant to most monoclonal a…

The Omicron variant was detected for the first time in South Africa in November 2021 and has since spread to many countries. It is expected to become the dominant variant...

Scientists identify antibodies that can neutralize…

An international team of scientists have identified antibodies that neutralize omicron and other SARS-CoV-2 variants. These antibodies target areas of the virus spike pro...

Pfizer and BioNTech sign new global collaboration …

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced a new research, development and commercialization collaboration to develop a potential first mRNA-based v...

Novartis and Molecular Partners report positive to…

Novartis and Molecular Partners announced that Part A of the EMPATHY clinical trial(1) that compared single intravenous doses of ensovibep, a DARPin antiviral therapeutic...

Bayer and Mammoth Biosciences to collaborate on no…

Bayer AG and Mammoth Biosciences, Inc., which is harnessing the diversity of nature to power the next-generation CRISPR products, today announced a strategic collaboratio...

Amgen and Arrakis Therapeutics announce multi-targ…

Amgen (NASDAQ:AMGN) and Arrakis Therapeutics today announced a research collaboration focused on the discovery and development of RNA degrader therapeutics against a rang...

Leiden University Medical Center and Intravacc to …

Intravacc, a global leader in translational research and development of therapeutic vaccines and vaccines against infectious diseases, today announced a partnership with ...

New Vaxzevria data further support its use as thir…

Positive results from a preliminary analysis of an ongoing safety and immunogenicity trial (D7220C00001) showed that Vaxzevria (ChAdOx1-S [Recombinant]), when given as a ...

AstraZeneca and Ionis close agreement to develop a…

AstraZeneca has closed a global development and commercialisation agreement with Ionis Pharmaceuticals, Inc. (Ionis) for eplontersen, formerly known as IONIS-TTR-LRX. ...